TransMedics Holdings Inc. (TMDX) has appointed Gerardo Hernandez as its new Chief Financial Officer, following a transition announced on December 2, 2024. The company also revised its financial outlook for fiscal year 2024, lowering its guidance by $5 million at the midpoint. Piper Sandler has maintained an 'Overweight' rating on TMDX, setting a price target of $110. The stock experienced a pre-market decline of 7.9%, reflecting investor concerns over the leadership change and the updated financial guidance. Additionally, the company is set to host its first investor day in New York City on December 10, 2024, where it aims to discuss its goal of reaching 10,000 organ transplants by 2028. TransMedics' stock has dropped 59% from its recent highs in less than four months, raising questions about its growth trajectory amidst increasing competition in organ perfusion technology.